TMEM2 inhibits the development of Graves’ orbitopathy through the JAK-STAT signaling pathway
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2023.105607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Hong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: lh2418@shutcm…. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
A mouse model was used to investigate the role of the hyaluronidase, transmembrane protein 2 (TMEM2), on the progression of Graves' orbital (GO) disease. We established a GO mouse model through immunization with a plasmid expressing the thyroid stimulating hormone receptor. Orbital fibroblasts (OFs) were subsequently isolated from both GO and non-GO mice for comprehensive in vitro analyses. The expression of TMEM2 was assessed using qRT-PCR, Western blot and immunohistochemistry in vivo. Disease pathology was evaluated by H&E staining and Masson's trichrome staining in GO mouse tissues. Our investigation revealed a notable reduction in TMEM2 expression in GO mouse orbital tissues. Through overexpression and knockdown assays, we demonstrated that TMEM2 suppresses inflammatory cytokines and reactive oxygen species production. TMEM2 also inhibits the formation of lipid droplets in OFs and the expression of adipogenic factors. Further incorporating Gene Set Enrichment Analysis of relevant GEO datasets and subsequent in vitro cell experiments, robustly confirmed that TMEM2 overexpression was associated with a pronounced upregulation of the JAK/STAT signaling pathway. In vivo, TMEM2 overexpression reduced inflammatory cell infiltration, adipogenesis, and fibrosis in orbital tissues. These findings highlight the varied regulatory role of TMEM2 in GO pathogenesis. Our study reveals that TMEM2 plays a crucial role in mitigating inflammation, suppressing adipogenesis, and reducing fibrosis in GO. TMEM2 has potential as a therapeutic target and biomarker for treating or alleviating GO. These findings advance our understanding of GO pathophysiology and provide opportunities for targeted interventions to modulate TMEM2 for therapeutic purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: lh2418@shutcm.edu.cn.
- Department of Endocrinology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Min, J., Yang, Y., Suo, W., Wang, W., Tian, J., & Qin, Y. (2024). TMEM2 inhibits the development of Graves’ orbitopathy through the JAK-STAT signaling pathway. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105607
Vancouver
Li H, Min J, Yang Y, Suo W, Wang W, Tian J, et al. TMEM2 inhibits the development of Graves’ orbitopathy through the JAK-STAT signaling pathway. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2023.105607
BibTeX
@article{Li2024,
author = {Li, Hong and Min, Jie and Yang, Yucheng and Suo, Wendong and Wang, Wei and Tian, Jiahe and Qin, Yujie},
title = {TMEM2 inhibits the development of Graves’ orbitopathy through the JAK-STAT signaling pathway},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2023.105607}
}
EUVIMED